Published online Sep 14, 2024. doi: 10.3748/wjg.v30.i34.3868
Revised: August 15, 2024
Accepted: August 22, 2024
Published online: September 14, 2024
Processing time: 103 Days and 8.7 Hours
This editorial builds on the article by Shakhshir et al. We conducted an overview of evidence-based dietary interventions in adults with inflammatory bowel di
Core Tip: Dietary therapies can be used to reduce inflammation or improve symptoms in patients with Crohn’s disease. The Mediterranean diet has been associated with improved outcomes in inflammatory bowel disease (IBD), and potentially reducing its development. Exclusive enteral nutrition and Crohn’s disease exclusion diet can be used for the induction of remission in Crohn’s disease. Multidisciplinary management of patients with IBD should include dietary advice and the involvement of experienced dietitians.
- Citation: Chen L, Srinivasan A, Vasudevan A. Examining dietary interventions in Crohn’s disease. World J Gastroenterol 2024; 30(34): 3868-3874
- URL: https://www.wjgnet.com/1007-9327/full/v30/i34/3868.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i34.3868
This editorial comments on the article ‘Global research trends on diet and nutrition in Crohn’s disease’ by Shakhshir et al[1]. Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic remitting and relapsing conditions of the gastrointestinal tract characterised by inflammation and an aberrant immune response[2]. The aetiology of IBD is postulated to involve a complex interplay between environmental and genetic factors[3]. Among the environmental factors, dietary factors have been implicated, including the use of dietary emulsifiers, poly-unsaturated fats, and ultra-processed foods[4,5]. Nutritional interventions are increasingly recognised as a critical component of comprehensive IBD care, encompassing strategies to mitigate disease symptoms, reduce inflammation, and correct nutritional deficiencies. Malnutrition is a significant concern in IBD patients due to factors such as poor gastrointestinal absorption, increased gastrointestinal losses, and a hypermetabolic state driven by chronic inflammation. These factors contribute to a high prevalence of micronutrient and macronutrient deficiencies, which can exacerbate disease related symptoms and impair patient reported quality of life[6,7].
As identified by Shakhshir et al[1], there is growing interest in dietary approaches in treating Crohn’s disease with a steady growth of publications in this field, however, further knowledge is required to strengthen recommendations in nutrition management in IBD. Landmark dietary trials in paediatric populations have been extrapolated for use in adult populations, however the role of dietary therapies is less certain given the presence of more heterogenous disease phenotype and variability in lifestyles. Hence, an awareness of the role and effectiveness of dietary therapies in IBD remains integral in making evidence-based recommendations to patients for managing IBD. This editorial focuses on the role of diet in Crohn’s disease in the adult population, as its efficacy in ulcerative colitis is less certain.
The multifactorial aetiology of IBD involves a dynamic interplay between genetic predisposition, environmental factors, immune dysregulation, and gut microbiota alterations. Among these, diet has emerged as a crucial environmental factor influencing the development and progression of IBD.
Epidemiological studies have consistently shown that dietary patterns can influence the pathogenesis of IBD[4]. In fact, Western dietary patterns characterised by high intake of refined sugars, fats, and processed foods and low intake of fibre have been associated with an increased IBD risk and more active disease[4]. Conversely, diets rich in fibre, fruits, vegetables, and anti-inflammatory nutrients such as omega-3 fatty acids and vitamin D have been associated with a lower risk of IBD[8].
The role of short-chain fatty acids, such as butyrate; a product of fermentation of dietary fibres with anti-inflammatory properties, is hypothesised to play a role in maintaining intestinal barrier integrity and gut homeostasis[9]. Studies also show that patients with IBD have lower levels of faecal short-chain fatty acids[9,10]. Dietary fats, including polyunsaturated fatty acids and omega-6 fatty acids from animal protein, excluding eggs and dairy, have also been implicated in incident cases of IBD[11].
As a modifiable lifestyle factor, diet presents an attractive therapeutic option due to its potential to improve quality of life with fewer perceived side effects than medical therapy. Moreover, patients often proactively initiate dietary modification, including self-restrictive diets, to manage their symptoms. In large scale questionnaires, up to two-thirds of patients report avoiding foods they enjoy to help prevent relapse of IBD[12] and majority (85.4%) of patients believed that diet triggers relapses[13]. Similarly, 59% of patients valued nutrition to be at least as important as pharmacotherapy for the management of IBD, including 62% who believed diet to be more important in influencing the disease course[14].
In addition, nearly half (43.8%) of patients describe dietary modifications, whether self-adjusted or clinician prescribed, to have significant interference in their social life[15]. From the clinicians’ perspective, diet is increasingly recognised as an adjunctive treatment to pharmacotherapy, and dietitians can play a pivotal role in multidisciplinary management of IBD when they are available. The lack of high-quality trials and scarcity of practical resources can limit the use of dietary therapies, with only a limited number of gastroenterologists actively incorporating dietary counselling into clinical practice[16].
Further work is required to bridge the gap between patient and clinician perceptions towards dietary therapy in IBD. A cross-sectional study of 928 patients found that 61% of patients felt their IBD specialist disregarded the importance of diet in their management. Only 26% reported receiving dietary advice from their doctor despite nearly all (98%) gastroenterologists surveyed reporting providing advice[17].
A key strategy is the inclusion of an experienced dietitian as standard of care in IBD management. Dietitians play an important role in the assessment and can tailor individualised plans in approaching malnutrition management, insti
The Mediterranean diet (MD), characterised by high consumption of fruits, vegetables, whole grains, legumes, fish, and olive oil, and low intake of red meat and processed foods, is the hallmark of lifestyle modifications and diet therapy in cardiovascular and metabolic health. It is associated with lower levels of systemic inflammation and oxidative stress markers in the general population[19,20].
MD’s dietary plan shares similarities with foods that have been implicated as protective factors and aims to avoid foods that have been implicated as risk factors for the development of IBD. A large-scale prospective cohort study has shown a lower risk of Crohn’s disease onset (HR = 0.42, 95%CI: 0.22-0.80) in participants adherent to the MD, but not ulcerative colitis (HR = 1.08, 95%CI: 0.74-1.58)[21].
In patients with active Crohn’s disease, the MD has shown similar rates of remission as induction therapy compared to the specific carbohydrate diet (SCD). A randomised trial involving patients with ileal (23.9%), colonic (17%), and ileocolonic (57.6%) disease showed 43.5% of the MD group achieving symptom remission at week 6, compared to 46.5% in the SCD group (P = 0.77). Faecal calprotectin response was not significantly different between the two groups (MD 30.8% vs SCD 43.88%; P = 0.83. Both diets were well tolerated, however adherence to a strict diet declined over time to 40% at week 12[22]. A randomised control trial of ulcerative colitis patients saw similar improvements in faecal calprotectin compared to an unrestricted diet (20% FC > 100 vs 75% FC > 100), with good tolerability[23].
Exclusive enteral nutrition (EEN) has emerged as a compelling therapeutic option in inducing remission and mucosal healing in Crohn’s disease without several of the adverse effects associated with pharmacotherapy. EEN involves the exclusive consumption of a nutritionally complete liquid formula while eliminating regular solid food intake. Common regimes include a six to eight week period of exclusive use following which a normal diet is gradually reintroduced. The mechanisms by which EEN exerts its beneficial effects are hypothesised to be related to modulation of the gut microbiota, reduction of intestinal permeability, anti-inflammatory effects, and providing bowel rest which could contribute to mucosal healing[16,24].
Several clinical trials have established EEN as an effective first-line therapy for inducing remission in Crohn’s disease. A randomised controlled trial by Borrelli et al[25] demonstrated that a polymeric diet was more effective than corticosteroids (79% vs 67%) in inducing healing in a paediatric population. Subsequent studies have supported these findings showing improvement in biochemical and endoscopic response rates and nutritional parameters without side effects[26-29].
In adult populations, the data is less robust and larger studies have not been able to recreate the same degree of efficacy. A meta-analysis demonstrated that EEN was not superior in efficacy to steroids as induction therapy in an adult population, with adverse events including nausea, vomiting, diarrhoea and bloating. Palatability and inability to tolerate EEN with symptoms of nausea, vomiting and fatigue were common reasons for withdrawal[30,31]. Early reports su
Dissatisfication with not being able to eat food, especially on social occasions, also contributed to poor adherence[33]. This highlights that the implementation of EEN can be challenging, and adherence can be difficult over extended periods.
EEN can also be used as a steroid-sparing therapy, including as an adjunctive therapy to optimise nutrition and reduce post-operative complications in malnourished patients prior to elective IBD related bowel surgery, or for refractory disease in conjunction with medical therapy[34].
The Crohn’s disease exclusion diet (CDED) is a structured diet that aims to reduce gut inflammation by excluding certain foods known to exacerbate symptoms and possibly trigger immune responses and gut dysbiosis. This diet focuses on eliminating specific food components, such as gluten, dairy, processed foods, and certain additives, while encouraging the consumption of fruits, vegetables, lean proteins, and other nutrient-dense foods.
A study of forty-four adults with mild-moderate Crohn’s disease showed 57% clinical remission at week 6, and 68% when combined with partial enteral nutrition. Eighty percent of those in remission at week 6 maintained clinical remission at week 24, with 35% in endoscopic remission at the time[35]. Earlier paediatric studies demonstrated an increase in steroid-free remission in patients with CDED, with augmentation of the effect when partial enteral nutrition was added[24,36].
One of the key strengths of the CDED is its ability to provide balanced and adequate intake of essential nutrients unlike highly restrictive diets that may lead to nutritional deficiencies. The CDED is implemented in phases, allowing for gradual reintroduction of excluded foods. This phased approach helps in identifying specific dietary triggers and maintaining long-term adherence.
CDED provides a good alternative where there is intolerance to EEN with improved compliance (85% vs 63%)[35]. Consensus agreements recommend supplementation with enteral nutrition to meet nutritional requirements and diet reintroduction after 12 weeks of therapy to avoid malnutrition[37].
The SCD is a nutritional regimen that restricts the intake of complex carbohydrates, and promotes the consumption of monosaccharides, which are easily absorbed and purported to minimise microbial dysbiosis. It is based on the theory that certain carbohydrates are not completely digested and absorbed, leading to fermentation and growth of pathogenic bacteria in the intestines.
In the paediatric populations with Crohn’s disease, studies have observed clinical and laboratory improvements following SCD therapy as well as significant changes in the faecal microbiome[38,39]. Use of the SCD has been shown to increase populations of beneficial bacteria and decrease inflammatory markers in a paediatric population with active Crohn’s disease[40]. A randomised trial comparing SCD with the MD in adult patients with Crohn’s disease found similar rates of early remission at week 6 (46.5% vs 43.5%) with a faecal calprotectin reduction in 34.8% and 30.8% respectively[22]. However, there are limited controlled studies comparing SCD to an unrestricted diet, limiting its widespread take-up as first-line dietary therapy in IBD.
Potential drawbacks from using the SCD long-term include its restrictive nature given elimination of sugars, high-lactose dairy and starchy vegetables.
The low FODMAP diet, initially developed for the management of irritable bowel syndrome (IBS), has increasingly been examined for its potential benefits in patients with IBD. This dietary intervention focuses on reducing the intake of carbohydrates that are poorly absorbed in the small intestine and highly fermentable, potentially exacerbating symptoms like bloating, gas, and abdominal pain through luminal distension and altered gut motility[41]. Given the overlap in symptoms between IBS and IBD, particularly during quiescent phases of the latter, the low FODMAP diet has been considered a valuable nutritional approach for symptom management in IBD patients.
Low FODMAP diet was beneficial for symptom management in IBD, with approximately half of patients finding improvement in symptoms of abdominal pain, bloating, wind, and diarrhoea. Compliance can be a limiting factor in its widespread use and lower compliance has been associated with a lack of efficacy[42-44]. A systematic review of 319 patients in IBD (96% in remission) found a significant improvement in diarrhoea, satisfaction of gut symptoms, bloating, pain, fatigue; however did not improve constipation[45].
The role of the low FODMAP diet on long-term disease outcomes and inflammation remains under investigation and it currently cannot be recommended as a treatment of IBD but rather as an adjuvant treatment for symptomatic improvement. Furthermore, it may not be suitable for those with severe disease due to the risk of nutrient deficiencies and potential impact on disease activity. Its sustainability can be challenging due to its restrictive nature, with long-term adherence diminishing over time.
Reduced dietary intake due to anorexia, nausea, and abdominal pain, combined with malabsorption and increased metabolic demands, contribute to macronutrient and energy deficits. Comprehensive nutritional assessment, including regular monitoring of body weight, body composition, and laboratory markers of nutritional status, is essential for identifying and addressing nutrient deficiencies in IBD patients. The use of screening tools such as the Malnutrition Universal Screenng Tool, Saskatchewan IBD-nutrition risk and Subjective Global Assessment can help clinicians identify at-risk patients and tailor nutritional interventions accordingly[46,47]. A cross-sectional study of over 200 patients with IBD found malnutrition rates of 27%-37%[48].
Iron deficiency is prevalent due to chronic intestinal bleeding, reduced iron absorption, and inflammation-induced alterations in iron metabolism. Routine screening allows for early detection, and management with intravenous iron therapy is shown to be more effective and better tolerated than oral iron[49,50]. Low vitamin D levels are associated with increased disease activity and a higher risk of hospitalisation and surgery in IBD patients, highlighting the need for regular monitoring and supplementation[51]. A prospective study showed low micronutrient levels were common even in quiescent disease; vitamin D was the most common deficiency (29%), followed by zinc (16%), vitamin B6 (14%), vitamin C (13%) and vitamin B12 (11%)[52]. Folate and vitamin B12 deficiencies are also common, especially with ileal Crohn’s or post-ileal resection[53]. Regular monitoring and supplementation of these vitamins were necessary to prevent anaemia and neurological complications.
The role of diet in IBD is increasingly recognised as an area of importance by clinicians and patients alike. This is an evolving field so there may be disparities in perceptions and attitudes toward diet between patients and clinicians which may partially relate to differences in how information is acquired. For example, patients may revert to social media, online forums, and patient advocacy groups for dietary advice while clinicians may rely on peer-reviewed journals, clinical guidelines, and professional societies for guidance. Improved awareness, communication and education, the development of evidence-based dietary guidelines, and the inclusion of dietitians in IBD care are integral steps in bridging this gap so that nutritional therapy can be optimised for patients with IBD.
Dietary therapies are an important element of IBD management. It can provide wide ranging benefits in improving nutritional outcomes, alleviating symptoms and sometimes improving inflammation. Evidence supports the integration of nutritional care into standard IBD management protocols, emphasising the need for multidisciplinary approaches that include dietitians and nutrition specialists. As further research and interest grows, integrating dietary knowledge and therapies in IBD care is adding to the potential strategies for optimising outcomes in IBD.
1. | Shakhshir M, Zyoud SH. Global research trends on diet and nutrition in Crohn's disease. World J Gastroenterol. 2023;29:3203-3215. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
2. | Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2693] [Cited by in F6Publishing: 2704] [Article Influence: 122.9] [Reference Citation Analysis (2)] |
3. | Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91-99. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 751] [Cited by in F6Publishing: 867] [Article Influence: 86.7] [Reference Citation Analysis (15)] |
4. | Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, Wu GD. Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology. 2015;148:1087-1106. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 246] [Cited by in F6Publishing: 265] [Article Influence: 29.4] [Reference Citation Analysis (0)] |
5. | Godny L, Dotan I. Is the Mediterranean Diet in Inflammatory Bowel Diseases Ready for Prime Time? J Can Assoc Gastroenterol. 2024;7:97-103. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
6. | Weisshof R, Chermesh I. Micronutrient deficiencies in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2015;18:576-581. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 129] [Cited by in F6Publishing: 150] [Article Influence: 16.7] [Reference Citation Analysis (0)] |
7. | Hartman C, Eliakim R, Shamir R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J Gastroenterol. 2009;15:2570-2578. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 141] [Cited by in F6Publishing: 130] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
8. | Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology. 2013;145:970-977. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 464] [Cited by in F6Publishing: 407] [Article Influence: 37.0] [Reference Citation Analysis (0)] |
9. | Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine. 2021;66:103293. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 63] [Cited by in F6Publishing: 293] [Article Influence: 97.7] [Reference Citation Analysis (0)] |
10. | Machiels K, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275-1283. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1036] [Cited by in F6Publishing: 1186] [Article Influence: 118.6] [Reference Citation Analysis (2)] |
11. | Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault MC, Carbonnel F. Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study. Am J Gastroenterol. 2010;105:2195-2201. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 268] [Cited by in F6Publishing: 278] [Article Influence: 19.9] [Reference Citation Analysis (0)] |
12. | Zallot C, Quilliot D, Chevaux JB, Peyrin-Biroulet C, Guéant-Rodriguez RM, Freling E, Collet-Fenetrier B, Williet N, Ziegler O, Bigard MA, Guéant JL, Peyrin-Biroulet L. Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis. 2013;19:66-72. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 123] [Cited by in F6Publishing: 151] [Article Influence: 13.7] [Reference Citation Analysis (0)] |
13. | Godala M, Gaszyńska E, Durko Ł, Małecka-Wojciesko E. Dietary Behaviors and Beliefs in Patients with Inflammatory Bowel Disease. J Clin Med. 2023;12. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
14. | de Vries JHM, Dijkhuizen M, Tap P, Witteman BJM. Patient's Dietary Beliefs and Behaviours in Inflammatory Bowel Disease. Dig Dis. 2019;37:131-139. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 82] [Cited by in F6Publishing: 59] [Article Influence: 9.8] [Reference Citation Analysis (0)] |
15. | Tay S, Chan PWW, Wei SC, Tan M, Hilmi IN, Leong JWH, Tan YY, Lim CT, Ling KL, Tey TT, Tan CK, Leong RWL, Lim WC, Hartono JL, Shim HH, Ong D, Ooi CJ, Salazar E. P579 Dietary beliefs, barriers, and acceptability of diet in IBD patients – a multi-centre survey from the Asia-Pacific region. J Crohns Colitis. 2024;18:i1130-1130. [DOI] [Cited in This Article: ] |
16. | Lee D, Baldassano RN, Otley AR, Albenberg L, Griffiths AM, Compher C, Chen EZ, Li H, Gilroy E, Nessel L, Grant A, Chehoud C, Bushman FD, Wu GD, Lewis JD. Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease. Inflamm Bowel Dis. 2015;21:1786-1793. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 11.9] [Reference Citation Analysis (0)] |
17. | Holt DQ, Strauss BJ, Moore GT. Patients with inflammatory bowel disease and their treating clinicians have different views regarding diet. J Hum Nutr Diet. 2017;30:66-72. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis (0)] |
18. | Fitzpatrick JA, Melton SL, Yao CK, Gibson PR, Halmos EP. Dietary management of adults with IBD - the emerging role of dietary therapy. Nat Rev Gastroenterol Hepatol. 2022;19:652-669. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 34] [Article Influence: 17.0] [Reference Citation Analysis (0)] |
19. | Martínez-González MA, Gea A, Ruiz-Canela M. The Mediterranean Diet and Cardiovascular Health. Circ Res. 2019;124:779-798. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 272] [Cited by in F6Publishing: 408] [Article Influence: 81.6] [Reference Citation Analysis (0)] |
20. | Shivappa N, Hebert JR, Marcos A, Diaz LE, Gomez S, Nova E, Michels N, Arouca A, González-Gil E, Frederic G, González-Gross M, Castillo MJ, Manios Y, Kersting M, Gunter MJ, De Henauw S, Antonios K, Widhalm K, Molnar D, Moreno L, Huybrechts I. Association between dietary inflammatory index and inflammatory markers in the HELENA study. Mol Nutr Food Res. 2017;61. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 157] [Cited by in F6Publishing: 176] [Article Influence: 25.1] [Reference Citation Analysis (0)] |
21. | Khalili H, Håkansson N, Chan SS, Chen Y, Lochhead P, Ludvigsson JF, Chan AT, Hart AR, Olén O, Wolk A. Adherence to a Mediterranean diet is associated with a lower risk of later-onset Crohn's disease: results from two large prospective cohort studies. Gut. 2020;69:1637-1644. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 90] [Cited by in F6Publishing: 117] [Article Influence: 29.3] [Reference Citation Analysis (0)] |
22. | Lewis JD, Sandler RS, Brotherton C, Brensinger C, Li H, Kappelman MD, Daniel SG, Bittinger K, Albenberg L, Valentine JF, Hanson JS, Suskind DL, Meyer A, Compher CW, Bewtra M, Saxena A, Dobes A, Cohen BL, Flynn AD, Fischer M, Saha S, Swaminath A, Yacyshyn B, Scherl E, Horst S, Curtis JR, Braly K, Nessel L, McCauley M, McKeever L, Herfarth H; DINE-CD Study Group. A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. Gastroenterology. 2021;161:837-852.e9. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 140] [Cited by in F6Publishing: 133] [Article Influence: 44.3] [Reference Citation Analysis (0)] |
23. | Haskey N, Estaki M, Ye J, Shim RK, Singh S, Dieleman LA, Jacobson K, Gibson DL. A Mediterranean Diet Pattern Improves Intestinal Inflammation Concomitant with Reshaping of the Bacteriome in Ulcerative Colitis: A Randomised Controlled Trial. J Crohns Colitis. 2023;17:1569-1578. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis (0)] |
24. | Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019;157:440-450.e8. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 289] [Cited by in F6Publishing: 354] [Article Influence: 70.8] [Reference Citation Analysis (0)] |
25. | Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol. 2006;4:744-753. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 313] [Cited by in F6Publishing: 302] [Article Influence: 16.8] [Reference Citation Analysis (0)] |
26. | Grover Z, Muir R, Lewindon P. Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol. 2014;49:638-645. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 13.1] [Reference Citation Analysis (0)] |
27. | Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21:1609-1614. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 6.9] [Reference Citation Analysis (0)] |
28. | Miller T, Suskind DL. Exclusive enteral nutrition in pediatric inflammatory bowel disease. Curr Opin Pediatr. 2018;30:671-676. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
29. | Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig Liver Dis. 2006;38:381-387. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 133] [Cited by in F6Publishing: 127] [Article Influence: 7.1] [Reference Citation Analysis (0)] |
30. | Narula N, Dhillon A, Zhang D, Sherlock ME, Tondeur M, Zachos M. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2018;4:CD000542. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 60] [Cited by in F6Publishing: 91] [Article Influence: 15.2] [Reference Citation Analysis (0)] |
31. | Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol. 2013;19:7652-7660. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 103] [Article Influence: 9.4] [Reference Citation Analysis (1)] |
32. | Xu Y, Guo Z, Cao L, Xie T, Shen W, Li Y, Gong J, Zhu W. Isolated colonic Crohn's disease is associated with a reduced response to exclusive enteral nutrition compared to ileal or ileocolonic disease. Clin Nutr. 2019;38:1629-1635. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
33. | Melton SL, Fitzpatrick JA, Taylor KM, Halmos EP, Gibson PR. Lessons from an audit of exclusive enteral nutrition in adult inpatients and outpatients with active Crohn's disease: a single-centre experience. Frontline Gastroenterol. 2023;14:6-12. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
34. | Hashash JG, Elkins J, Lewis JD, Binion DG. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review. Gastroenterology. 2024;166:521-532. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Reference Citation Analysis (0)] |
35. | Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, Cohen NA, Ron Y, Goren I, Leibovitzh H, Wardi J, Zittan E, Ziv-Baran T, Abramas L, Fliss-Isakov N, Raykhel B, Gik TP, Dotan I, Maharshak N. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022;7:49-59. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 86] [Article Influence: 28.7] [Reference Citation Analysis (0)] |
36. | Sigall Boneh R, Sarbagili Shabat C, Yanai H, Chermesh I, Ben Avraham S, Boaz M, Levine A. Dietary Therapy With the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy. J Crohns Colitis. 2017;11:1205-1212. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 102] [Cited by in F6Publishing: 112] [Article Influence: 16.0] [Reference Citation Analysis (0)] |
37. | Russell EE, Day AS, Dimitroff C, Trakman GL, Silva H, Bryant RV, Purcell L, Yao CK, Landorf E, Fitzpatrick JA. Practical application of the Crohn's disease exclusion diet as therapy in an adult Australian population. J Gastroenterol Hepatol. 2024;39:446-456. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
38. | Suskind DL, Lee D, Kim YM, Wahbeh G, Singh N, Braly K, Nuding M, Nicora CD, Purvine SO, Lipton MS, Jansson JK, Nelson WC. The Specific Carbohydrate Diet and Diet Modification as Induction Therapy for Pediatric Crohn's Disease: A Randomized Diet Controlled Trial. Nutrients. 2020;12. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 31] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
39. | Burgis JC, Nguyen K, Park KT, Cox K. Response to strict and liberalized specific carbohydrate diet in pediatric Crohn's disease. World J Gastroenterol. 2016;22:2111-2117. [PubMed] [DOI] [Cited in This Article: ] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis (1)] |
40. | Cohen SA, Gold BD, Oliva S, Lewis J, Stallworth A, Koch B, Eshee L, Mason D. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014;59:516-521. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 155] [Cited by in F6Publishing: 148] [Article Influence: 14.8] [Reference Citation Analysis (0)] |
41. | Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146:67-75.e5. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 810] [Cited by in F6Publishing: 763] [Article Influence: 76.3] [Reference Citation Analysis (0)] |
42. | Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis. 2009;3:8-14. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 219] [Cited by in F6Publishing: 210] [Article Influence: 14.0] [Reference Citation Analysis (1)] |
43. | Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H, Levenez F, Pons N, Maziers N, Lomer MC, Ehrlich SD, Irving PM, Whelan K. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Gastroenterology. 2020;158:176-188.e7. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 153] [Cited by in F6Publishing: 196] [Article Influence: 49.0] [Reference Citation Analysis (0)] |
44. | Prince AC, Myers CE, Joyce T, Irving P, Lomer M, Whelan K. Fermentable Carbohydrate Restriction (Low FODMAP Diet) in Clinical Practice Improves Functional Gastrointestinal Symptoms in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:1129-1136. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 119] [Cited by in F6Publishing: 120] [Article Influence: 15.0] [Reference Citation Analysis (0)] |
45. | Zhan YL, Zhan YA, Dai SX. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clin Nutr. 2018;37:123-129. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis (0)] |
46. | Haskey N, Peña-Sánchez JN, Jones JL, Fowler SA. Development of a screening tool to detect nutrition risk in patients with inflammatory bowel disease. Asia Pac J Clin Nutr. 2018;27:756-762. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 10] [Reference Citation Analysis (1)] |
47. | Stratton RJ, Hackston A, Longmore D, Dixon R, Price S, Stroud M, King C, Elia M. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. Br J Nutr. 2004;92:799-808. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 682] [Cited by in F6Publishing: 725] [Article Influence: 36.3] [Reference Citation Analysis (0)] |
48. | Taylor LM, Eslamparast T, Farhat K, Kroeker K, Halloran B, Shommu N, Kumar A, Fitzgerald Q, Gramlich L, Abraldes JG, Tandon P, Raman M. Using Patient Completed Screening Tools to Predict Risk of Malnutrition in Patients With Inflammatory Bowel Disease. Crohns Colitis 360. 2021;3:otab043. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
49. | Gasche C, Berstad A, Befrits R, Beglinger C, Dignass A, Erichsen K, Gomollon F, Hjortswang H, Koutroubakis I, Kulnigg S, Oldenburg B, Rampton D, Schroeder O, Stein J, Travis S, Van Assche G. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545-1553. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 301] [Cited by in F6Publishing: 301] [Article Influence: 17.7] [Reference Citation Analysis (3)] |
50. | Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116 Suppl 7A:44S-49S. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 144] [Cited by in F6Publishing: 148] [Article Influence: 7.4] [Reference Citation Analysis (0)] |
51. | Ananthakrishnan AN, Khalili H, Higuchi LM, Bao Y, Korzenik JR, Giovannucci EL, Richter JM, Fuchs CS, Chan AT. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology. 2012;142:482-489. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 286] [Cited by in F6Publishing: 302] [Article Influence: 25.2] [Reference Citation Analysis (0)] |
52. | MacMaster MJ, Damianopoulou S, Thomson C, Talwar D, Stefanowicz F, Catchpole A, Gerasimidis K, Gaya DR. A prospective analysis of micronutrient status in quiescent inflammatory bowel disease. Clin Nutr. 2021;40:327-331. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
53. | Yakut M, Ustün Y, Kabaçam G, Soykan I. Serum vitamin B12 and folate status in patients with inflammatory bowel diseases. Eur J Intern Med. 2010;21:320-323. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 8.2] [Reference Citation Analysis (0)] |